提醒

提醒专业图表

Outlook Therapeutics Inc. (OTLK)

NasdaqCM: OTLK · 实时价格 · USD

0.76

-0.13 (-14.61%)

收盘价： Aug 14, 2026, 3:59 PM

0.80

+5.62%

盘后: 7:59 PM

-14.61% (1D)

买价	n/a
市值	141.44M
营收（TTM）	333.14K
净利润（TTM）	-60.96M
贝塔值	0.80
每股收益（TTM）	-1.13
市盈率（TTM）	n/a
预期市盈率	-4.73
市净率（TTM）	-2.73
市销率（TTM）	424.58
Earnings Date	n/a

卖价	n/a
成交量	104,398,955
20日均量	24,060,754
开盘价	0.84
前收盘价	0.89
日内区间	0.71 - 0.84
52周区间	0.16 - 3.39
分析师	n/a
目标价	5 (557.89%)
分红	n/a
除息日	n/a

关于 OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has col...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Jun 14, 2016

员工人数 17

交易所 NasdaqCM

股票代码 OTLK

官网 https://outlooktherapeutics.com

公司完整简介

财务表现

2025年，Outlook Therapeutics的营收为1.41M，较上一年的0增长undefined%。净利润为-62.42M，下降-17.17%。

财务报表

分析师预测

根据4位分析师的评级，OTLK的平均评级为“null”。12个月目标价为5，较最新价格上涨空间557.89%。

股票预测

财报意外

新

Outlook Therapeutics 已于 Aug 14, 2026 发布季度财报：

营收为 $127.44K 低于预期 $0, ， Infinity% 同比增长.

每股收益为 -0.09 低于预期 -0.02, ， 79.55% 同比增长.

新闻

刚刚 · Simply Wall St.

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Outlook Therapeutics stock has been through a very rough stretch over the past few years, and the current checks suggest it still does not screen as a clear bargain despite the recent approval and upc...

14小时前 · MarketBeat

Oncobiologics Q3 Earnings Call Highlights

Oncobiologics (NASDAQ:OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation ...

16小时前 · Moby

Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary

Moby summary of Outlook Therapeutics, Inc.'s Q3 2026 earnings call

17小时前 · Zacks

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the sto...

1天前 · Stocktwits

Why Did OTLK Stock Crash In Pre-Market Today?

Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.

第 1 页，共 2 页

Outlook Therapeutics Inc. (OTLK)